This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a component of the U.S. Department of Veterans Affairs (VA), to Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.). The $15,000,000 single-award BPA has a period of performance from September 2024 through September 2025 and is for the provision of the oncology drugs BALVERSA (erdafitinib) and CARVYKTI (ciltacabtagene autoleucel).
Janssen Biotech is a major pharmaceutical manufacturer that specializes in biologic therapies, particularly for cancer, immunology, and infectious diseases. The company holds several significant federal contract Indefinite Delivery Vehicles (IDVs) with the VA, including a $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs, as well as other BPAs for oncology medications such as BALVERSA and WELIREG (belzutifan). These IDVs allow the VA and its various Veterans Integrated Service Networks (VISNs) to efficiently procure a steady supply of essential specialty drugs to support the comprehensive healthcare needs of veteran patients nationwide.
Generated 11/26/24, 9:05 AM